Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2022-09-07 Director's Dealing
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the change in share ownership by an executive (Sujeen Lee) of SK Bioscience. This type of filing is a standard regulatory requirement for insider trading or changes in holdings by company insiders, which corresponds to the 'Director's Dealing' category.
2022-09-07 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Audit Report / Information Classification · 1% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by SK Bioscience. It provides specific details on inter-company transactions, share ownership, and financial relationships within the SK corporate group for a specific quarter. This type of regulatory filing in South Korea is a mandatory disclosure of corporate group status and does not fit into categories like annual reports, earnings releases, or investor presentations. As it is a standard regulatory disclosure required by the Fair Trade Commission, it falls under the 'Regulatory Filings' category. Q2 2024
2022-08-31 Korean
투자판단관련주요경영사항(주사형 로타바이러스 백신 임상의 사전 계획된 1단계 무용성 중간평가에 따른 조기 중단)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding a material management decision (major business matter). It specifically announces the early termination of a Phase 3 clinical trial for a rotavirus vaccine due to a futility analysis. This falls under the category of regulatory announcements regarding business operations and material events, which is best classified as a Regulatory Filing (RNS) as it does not fit into specific categories like M&A, dividends, or director dealings.
2022-08-30 Korean
투자판단관련주요경영사항(노바백스 코로나19 백신 국내 품목허가 변경(만 12~17세 청소년 적응증 추가))
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding a change in product approval (COVID-19 vaccine indication for adolescents) by the Ministry of Food and Drug Safety. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it does not fit into specific categories like financial reports, dividends, or director dealings, it falls under the general regulatory filing category.
2022-08-12 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for SK Bioscience Co., Ltd. for the period ending 2022.06.30. It contains detailed financial statements, business descriptions, management analysis, and operational data. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (such as a half-year report) containing substantive financial data is classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-12 Korean
투자판단관련주요경영사항(COVID-19 백신 GBP510의 이종 부스터샷 네팔 제3상 임상시험계획(IND) 신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an Investigational New Drug (IND) application for a Phase 3 clinical trial of their COVID-19 vaccine (GBP510) in Nepal. Since this is a specific regulatory disclosure of a material event that does not fit into categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2022-08-08 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.